UPJOHN, LILLY & SCHERING-PLOUGH POST STRONG GAINS IN LACKLUSTER WEEK
UPJOHN, LILLY & SCHERING-PLOUGH POST STRONG GAINS IN LACKLUSTER WEEK Upjohn (up 1-3/4 to 54) and 1-3/8 jumps by Lilly and Schering-Plough, to 58-1/8 and 38, respectively, led pharmaceutical/health care issues during the week ended Aug. 17. With most stocks trading within a narrow range, only seven issues posted point-or-more gains on the week. The other strong performers were J&J (up 1-1/4 to 33-1/2), Pfizer (up 1-1/4 to 36-1/4), Erbamont (up 1-1/4 to 11-5/8) and Robins (up 1 to 15-1/4). Revlon jumped a point to 39-7/8 on Aug. 14 following the disclosure of British investor Alan Clore's purchase of 6.5% of the firm's common stock (see related T&G, this issue), but slipped back to close the week off 3/8 to 38-1/4. Revlon was the seventh most active issue on Aug. 14 on the NYSE with 930,500 shares changing hands. Chart omitted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth